Geron Initiates Randomized Phase 2 Clinical Trial Of Imetelstat In Breast Cancer
 

Geron Corporation (Nasdaq:GERN) today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), in combination with paclitaxel (with or without bevacizumab) in patients with locally recurrent or metastatic breast cancer...

More...